
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : hAd5 S+N
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : ImmunityBio
Deal Size : Undisclosed
Deal Type : Agreement
Amyris and ImmunityBio Complete Joint Venture for Next Generation COVID-19 RNA Vaccine
Details : The ability to ‘mix and match’ vaccine platforms through this new joint venture and ImmunityBio’s multiple COVID vaccine platforms represents one of the most exciting approaches to ending COVID-19 including hAd5 S+N.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
January 03, 2022
Lead Product(s) : hAd5 S+N
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : ImmunityBio
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : RNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Infectious Disease Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Amyris Achieves Promising in-vivo Results for Intranasal RNA Vaccine
Details : The Amyris/IDRI RNA technology may also support the potential for intranasal vaccine delivery that can protect against SARS-CoV-2 and other respiratory diseases, including the flu.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
August 20, 2021
Lead Product(s) : RNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Infectious Disease Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Infectious Disease Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preliminary data from a pre-clinical study of IDRI's Nanostructured Lipid Carrier (NLC) vaccine platform demonstrated a significant level of antibody production against the COVID-19 spike protein using a self-adjuvanting RNA vaccine.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 22, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Infectious Disease Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
